Clinical Trials Plus+ Project
It all begins with an idea. Our idea is turning all the “talk” about clinical trial diversity into measurable outcomes after new drugs or medical devices are approved by the U.S. Food & Drug Administration (FDA) and brought to market, thereby ensuring marginalized communities can actually access the products.
Ask yourself this question:
What good is a new product developed with diverse clinical trial participants if consumers have inequitable access to the drug or medical device?
Help us make an impact.
Interested in sharing your experience trying to access a new pharmaceutical product, or medical device? Whatever it is, your story can make all the difference.
Featured Opinions.
Pharmacoequity: a new goal for ending disparities in U.S. health care
By Utibe R. Essien | Published in STAT on July 28, 2021
Utibe R. Essien is a general internist, assistant professor of medicine at the University of Pittsburgh School of Medicine, and director of the Career Education and Enhancement for Health Care Research Diversity Program for Medical Students. The views expressed here are his alone and do not necessarily reflect those of his employer.
Featured News.
There’s a new, pill for postpartum depression, but many at-risk women face hurdles.
By Nada Hassanein | Published in Stateline on January 11, 2024
Suicide and overdoses are among the leading causes of maternal death in the U.S.